fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Tacrolimus

All products: Limited Use (codes 590)

Envarsus PA · DIN 02485877 · 0.75 mg · extended release tablet

Limited Use, Reason for Use code 590 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 590 required
Write on scriptReason for Use code 590 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 590
Reason for Use code 590 For the prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients in combination with other immunosuppressants. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Envarsus PA · DIN 02485877 Manufacturer: Endo Ventures Ltd.; listing date 2020-09-30 Health Canada: Marketed since 2026-03-23 · brand ENVARSUS PA · ATC L04AD02 TACROLIMUS · form Tablet (extended-release) · route Oral · ingredients TACROLIMUS 0.75 MG · company Knight therapeutics inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Envarsus PA: Formulary list price $2.10 per unit (the source does not state the unit; exact figure $2.0999). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02485877)

Source record
DIN 02485877: Envarsus PA Raw flags: sec12=Y, sec3=Y Item: 924400008; group id 1051; item number 2407; lccId 00340; manufacturer id EVL Source form: ER Tab; strength: 0.75mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0999; ministry $2.0999 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02485877 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97609
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (L04A): coverage varies; not interchangeable

  • Baricitinib (Olumiant): limited Use 615, 734, limited Use 734
  • Cladribine (Mavenclad): not a benefit
Other drugs in the same formulary class (92:44 Immunosuppressive Agents) and how they are covered

Matched class: 92:44 Immunosuppressive Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 92:44 Immunosuppressive Agents

BARICITINIB

· 2 products · Limited Use, codes 615, 734 (1), Limited Use, codes 734 (1) · strengths: 2mg, 4mg · Tab

CLADRIBINE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:44
Full class listing Related classes: 92:20 Biologic Response Modifiers, 92:36 Disease-Modifying Antirheumatic Agents, 92:92 Other Miscellaneous Therapeutic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: active rheumatoid arthritis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: LEFLUNOMIDE, PENICILLAMINE, SULFASALAZINE CYCLOSPORINE · Off-Formulary Interchangeable, not an ODB benefit (2), General benefit (8) Rheumatoid Arthritis NEORAL capsules and oral solution (cyclosporine) are also indicated for the treatment of severe active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents are inappropriate or ineffective. PM: https://pdf.hres.ca/dpd_pm/00085584.PDF; date 2026-07-30; DIN 02150662; fetched 2026-09-10 Product monograph LEFLUNOMIDE · General benefit ARAVA is indicated in adults for the treatment of active rheumatoid arthritis. 1.1 Pediatrics The use in patients less than 18 years of age is contraindicated. 1.2 Geriatrics No dosage adjustment is needed in patients over 65 years of age. PM: https://pdf.hres.ca/dpd_pm/00083555.PDF; date not captured; DIN 02241888; fetched 2026-09-10 Product monograph PENICILLAMINE · General benefit INDICATIONS AND CLINICAL USE CUPRIMINE (penicillamine capsules, USP) is indicated for:  treatment of Wilson's disease  chronic lead poisoning  cystinuria, and  In patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. PM: https://pdf.hres.ca/dpd_pm/00054287.PDF; date not captured; DIN 00016055; fetched 2026-09-10 Product monograph SULFASALAZINE · General benefit It is especially useful for chronic administration. pms-SULFASALAZINE-E.C. is also indicated for the treatment of active rheumatoid arthritis, when treatment with an adequate conventional first line therapy has failed. PM: https://pdf.hres.ca/dpd_pm/00056638.PDF; date April 30, 2020; DIN 00598461; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS Transplantation Prograf® (tacrolimus) is indicated for: • prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants. • treatment of refractory rejection in patients receiving allogeneic liver or kidney transplants. Prograf is to be used concomitantly with adrenal corticosteroids and other immunosuppressive agents. The safety and efficacy of the use of Prograf with sirolimus has not been established. Only physicians experienced in immunosuppressive therapy and management of organ transplant should prescribe Prograf (tacrolimus). Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient. Rheumatoid Arthritis Prograf (tacrolimus immediate-release capsules, USP) is indicated for: • treatment of active rheumatoid arthritis in adult patients for whom disease modifying anti-rheumatic drug (DMARD) therapy is ineffective or inappropriate. Prograf may be used as monotherapy or in combination with non-st… https://pdf.hres.ca/dpd_pm/00082912.PDF PM date: 2025-12-17 Source product: PROGRAF; DIN 02175983; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18